Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TASTER
2018-001843-29Phase 2Unknown
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Nov 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of tazemetostat, imatinib, nilotinib, dasatinib, bosutinib and 1 more in chronic myelogenous leukemia (CML) (5 arms), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Proportion of treatment responders. Status: unknown.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2018-001843-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001843-29.